Treatment of Clostridioides difficile infection: from guidelines to clinical practice

Autores de IIS La Fe

• Miguel Salavert Lletí

  Autor

Participantes ajenos a IIS La Fe

• Merino E.

Grupos

• Infección Grave

Abstract

The Clostridioides difficile Infection (CDI) treatment guidelines were published in 2021; however, the incorporation of these recommendations into clinical practice was rather irreg-ular and inconsistent. The differences in the implementation of these new guidelines were due, in part, to the variety in the different professionals who provided patient care, as well as to the issues involved in either their accessibility or availability or both. The main requirements for implementation include ap-propriate reflection on patient stratification, drug positioning, accessibility to drugs, as well as the organization of structured clinical pathways that can facilitate the functionality and evaluation of the management of CDI. © 2022, Sociedad Espanola de Quiminoterapia. All rights reserved.

Keywords

• Clostridioides difficile; Clostridium Infections; Humans; bezlotoxumab; daxomicin; fidaxomicin; metronidazole; proton pump inhibitor; rifaximin; unclassified drug; vancomycin; algorithm; Article; clinical practice; Clostridioides difficile; Clostridium difficile infection; fecal microbiota transplantation; follow up; hospitalization; human; intestine flora; paralytic ileus; patient care; practice guideline; propensity score; quality of life; recurrence risk; Clostridium infection